Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents
Austin N. Spratt, Fabio Gallazzi, Thomas P. Quinn, Christian L. Lorson, Anders Sönnerborg, Kamalendra Singh
Abstract
: Small molecule coronavirus helicase inhibitors represent attractive pharmacological modalities for the treatment of coronaviruses such as SARS-CoV and SARS-CoV-2. Rightfully so, the current emphasis is focused upon the development of vaccines. However, vaccines may not work for everyone and broad-based adoption of vaccinations is an increasingly challenging societal endeavor. Therefore, it is important to develop additional pharmacological antivirals against the highly conserved coronavirus helicases to broadly protect against this and subsequent coronavirus epidemics.
Topics & Concepts
HelicaseCoronavirusVirologyDrug discoverydnaB helicaseDrugPurineAntiviral drugBiologyChemistryVirusMedicineCoronavirus disease 2019 (COVID-19)PharmacologyDiseaseBiochemistryEnzymeInfectious disease (medical specialty)GeneRNAPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesComputational Drug Discovery Methods